Uridine nucleoside derivatives, compositions and methods of use

Patent metadata

Field	Value
Publication number	US-10544183-B2
Application number	US-201414775426-A
Country	US
Kind code	B2
Filing date	Mar 13, 2014
Priority date	Mar 13, 2013
Publication date	Jan 28, 2020
Grant date	Jan 28, 2020

Abstract

This disclosure relates to uridine nucleoside derivatives, compositions comprising therapeutically effective amounts of those nucleoside derivatives and methods of using those nucleoside derivatives or compositions in treating disorders that are responsive to ligands, such as agonists, of P 2 Y 6 receptor, e.g., neuronal disorders, including neurodegenerative disorders (e.g., Alzheimer's disease, Parkinson's disease) and traumatic CNS injury, pain, Down Syndrome (DS), glaucoma and inflammatory conditions.

First claim

What is claimed is:

1. A method of improving cognitive function in a subject in need thereof, wherein the subject in need thereof has Alzheimer's disease, comprising administering to the subject an effective amount of a composition comprising a compound of formula I:

or a salt thereof, wherein:
A is a bicyclic aromatic ring having up to 4 heteroatoms selected from N, O and S, wherein the bicyclic aromatic ring is independently and optionally substituted with one or more R 7 ;
X is selected from:
—H, —C(O)R 5 , and —C(O)OR 5 ;

Y is a bond or a (C1-C5)-aliphatic group independently and optionally substituted with one or more R 4 ;
Z and W are each independently selected from ═O, ═S, ═N(R 5 ), and ═NOR 5 ;
R 1 is selected from:
—H, halogen, —OR 5 , —CN, —CF 3 , —OCF 3 and a (C1-C6)-aliphatic group optionally substituted with one or more R 7 ;

R 2 and R 3 are each independently selected from —OR 5 , —SR 5 , —NR 5 R 6 , —OC(O)R 5 ,
—OC(O)NR 5 R 6 , and —OC(O)OR 5 ;
each occurrence of R 4 is independently selected from:
halogen, —OR 5 , —NO 2 , —CN, —CF 3 , —OCF 3 , —R 5 , 1,2-methylenedioxy, 1,2-ethylenedioxy, —N(R 5 ) 2 , —SR 5 , —SOR 5 , —SO 2 R 5 , —SO 2 N(R 5 ) 2 , —SO 3 R 5 , —C(O)R 5 , —C(O)C(O)R 5 , —C(O)CH 2 C(O)R 5 , —C(S)R 5 , —C(S)OR 5 , —C(O)OR 5 , —C(O)C(O)OR 5 , —C(O)C(O)N(R 5 ) 2 , —OC(O)R 5 , —C(O)N(R 5 ) 2 , —OC(O)N(R 5 ) 2 , —C(S)N(R 5 ) 2 , —(CH 2 ) 0-2 NHC(O)R 5 , —N(R 5 )N(R 5 )COR 5 , —N(R 5 )N(R 5 )C(O)OR 5 , —N(R 5 )N(R 5 )CON(R 5 ) 2 , —N(R 5 )SO 2 R 5 , —N(R 5 )SO 2 N(R 5 ) 2 , —N(R 5 )C(O)OR 5 , —N(R 5 )C(O)R 5 , —N(R 5 )C(S)R 5 , —N(R 5 )C(O)N(R 5 ) 2 , —N(R 5 )C(S)N(R 5 ) 2 , —N(COR 5 )COR 5 , —N(OR 5 )R 5 , —C(═NH)N(R 5 ) 2 , —C(O)N(OR 5 )R 5 , —C(═NOR 5 )R 5 , —OP(O)(OR 5 ) 2 , —P(O)(R 5 ) 2 , —P(O)(OR 5 ) 2 , and —P(O)(H)(OR 5 );

each occurrence of R 5 is independently selected from:
H—,
(C1-C12)-aliphatic-,
(C3-C10)-cycloalkyl- or -cycloalkenyl-,
[(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-aliphatic-,
(C6-C10)-aryl-,
(C6-C10)-aryl-(C1-C12)aliphatic-,
(C3-C10)-heterocyclyl-,
(C6-C10)-heterocyclyl-(C1-C12)aliphatic-,
(C5-C10)-heteroaryl-, and
(C5-C10)-heteroaryl-(C1-C12)-aliphatic-;

wherein two R 5 groups bound to the same atom optionally form a 3- to 10-membered aromatic or non-aromatic ring having up to 3 heteroatoms independently selected from N, O, S, SO, and SO 2 , wherein said ring is optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or a (C3-C10)heterocyclyl; and
wherein each R 5 group is independently and optionally substituted with one or more R 7 ;
R 6 is selected from:
—R 5 , —C(O)R 5 , —C(O)OR 5 , —C(O)N(R 5 ) 2 and —S(O) 2 R 5 ;

each occurrence of R 7 is independently selected from:
halogen, —OR 8 , —NO 2 , —CN, —CF 3 , —OCF 3 , —R 8 , oxo, thioxo, 1, 2-methylenedioxy, 1,2-ethylenedioxy, —N(R 8 ) 2 , —SR 8 , —SOR 8 , —SO 2 R 8 , —SO 2 N(R 8 ) 2 , —SO 3 R 8 , —C(O)R 8 , —C(O)C(O)R 8 , —C(O)CH 2 C(O)R 8 , —C(S)R 8 , —C(S)OR 8 , —C(O)OR 8 , —C(O)C(O)OR 8 , —C(O)C(O)N(R 8 ) 2 , —OC(O)R 8 , —C(O)N(R 8 ) 2 , —OC(O)N(R 8 ) 2 , —C(S)N(R 8 ) 2 , —(CH 2 )o- 2 NHC(O)R 8 , —N(R 8 )N(R 8 )COR 8 , —N(R 8 )N(R 8 )C(O)OR 8 , —N(R 8 )N(R 8 )CON(R 8 ) 2 , —N(R 8 )SO 2 R 8 , —N(R 8 )SO 2 N(R 8 ) 2 , —N(R 8 )C(O)OR 8 , —N(R 8 )C(O)R 8 , —N(R 8 )C(S)R 8 , —N(R 8 )C(O)N(R 8 ) 2 , —N(R 8 )C(S)N(R 8 ) 2 , —N(COR 8 )COR 8 , —N(OR 8 )R 8 , —C(═NH)N(R 8 ) 2 , —C(O)N(OR 8 )R 8 , —C(═NOR 8 )R 8 , —OP(O)(OR 8 ) 2 , —P(O)(R 8 ) 2 , —P(O)(OR 8 ) 2 , and —P(O)(H)(OR 8 );

each occurrence of R 8 is independently selected from:
H— and (C1-C6)-aliphatic-,
and an acceptable carrier, adjuvant or excipient.

2. The method of claim 1 , wherein A of said compound of Formula I is selected from the group consisting of:

wherein A is optionally further substituted with one or more R 7 .

3. The method of claim 1 , wherein A of said compound of Formula I is

wherein A is optionally further substituted with one or more R 7 .

4. The method of claim 1 , wherein X of said compound of Formula I is —H or —C(O)R 5 .

5. The method of claim 1 , wherein R 1 of said compound of Formula I is H, bromine, iodine, methyl, ethyl or CF 3 .

6. The method of claim 1 , wherein R 1 is —H.

7. The method of claim 1 , wherein Z of said compound of Formula I is ═O or ═S.

8. The method of claim 1 , wherein Z is ═O.

9. The method of claim 1 , wherein W of said compound of Formula I is ═O or ═S.

10. The method of claim 1 , wherein W is ═O.

11. The method of claim 1 , wherein Y of said compound of Formula I is a C1-aliphatic group optionally substituted with one or more R 4 .

12. The method of claim 1 , wherein Y is —CH 2 —.

13. The method of claim 1 , wherein R 2 of said compound of Formula I is —OR 5 .

14. The method of claim 1 , wherein R 2 is —OH.

15. The method of claim 1 , wherein R 3 of said compound of Formula I is —OR 5 .

16. The method of claim 1 , wherein R 3 is —OH.

17. The method of claim 1 , wherein said compound is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

18. The method of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

19. A method of enhancing the rate of beta amyloid clearance in a subject in need thereof, wherein the subject in need thereof has Alzheimer's disease, comprising administering an effective amount of a composition comprising a compound of formula I

or a salt thereof, wherein:
A is a bicyclic aromatic ring having up to 4 heteroatoms selected from N, O and S, wherein the bicyclic aromatic ring is independently and optionally substituted with one or more R 7 ;
X is selected from:
—H, —C(O)R 5 , and —C(O)OR 5 ;

Y is a bond or a (C1-C5)-aliphatic group independently and optionally substituted with one or more R 4 ;
Z and W are each independently selected from ═O, ═S, ═N(R 5 ), and ═NOR 5 ;
R 1 is selected from:
—H, halogen, —OR 5 , —CN, —CF 3 , —OCF 3 and a (C1-C6)-aliphatic group optionally substituted with one or more R 7 ;

R 2 and R 3 are each independently selected from —OR 5 , —SR 5 , —NR 5 R 6 , —OC(O)R 5 , —OC(O)NR 5 R 6 , and —OC(O)OR 5 ;
each occurrence of R 4 is independently selected from:
halogen, —OR 5 , —NO 2 , —CN, —CF 3 , —OCF 3 , —R 5 , 1,2-methylenedioxy, 1,2-ethylenedioxy, —N(R 5 )

Assignees

• Univ Tufts
• Haydon Philip G
• Lee Jinbo

Inventors

• Haydon Philip G
• Lee Jinbo

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P27/06

  Antiglaucoma agents or miotics · CPC title